新鲜组织培养试验与单克隆抗体在肾细胞癌体内定位的比较。

Comparison of fresh tissue incubation assay and the in vivo localization of monoclonal antibodies to renal cell carcinoma.

作者信息

Chiou R K, Vessella R L, Elson M K, Palme D F, Lange P H

出版信息

J Urol. 1987 Jun;137(6):1274-7. doi: 10.1016/s0022-5347(17)44481-8.

Abstract

Few in vitro tests currently available are able to accurately predict the in vivo localization of monoclonal antibodies (Mabs) to cancer. We report on a fresh tissue incubation assay (FTIA) and compare the results of this assay to the in vivo localization of renal cell carcinoma (RCC)-reactive Mab A6H and control Mab AFP-22 to RCC and non-RCC xenografts implanted in nude mice. Both the FTIA and in vivo localization study demonstrated highly selective uptake of A6H in RCC but not in non-RCC xenografts. Radioimmunoscintigraphy using A6H clearly visualized RCC xenografts in every attempt, while AFP-22 did not highlight any of the tumor xenografts. The results demonstrate that FTIA may be a useful in vitro assay for selecting Mabs for in vivo application, and that radioimmunoscintigraphy is a potentially useful tool in detecting cancer sites.

摘要

目前可用的体外试验中，很少有能够准确预测单克隆抗体（Mab）在癌症体内的定位情况。我们报告了一种新鲜组织孵育试验（FTIA），并将该试验的结果与肾细胞癌（RCC）反应性单克隆抗体A6H以及对照单克隆抗体AFP-22在植入裸鼠体内的RCC和非RCC异种移植瘤中的体内定位结果进行了比较。FTIA和体内定位研究均表明，A6H在RCC中具有高度选择性摄取，而在非RCC异种移植瘤中则没有。使用A6H的放射免疫闪烁显像在每次尝试中都能清晰地显示RCC异种移植瘤，而AFP-22则未突出显示任何肿瘤异种移植瘤。结果表明，FTIA可能是一种用于选择体内应用单克隆抗体的有用体外试验，并且放射免疫闪烁显像在检测癌症部位方面是一种潜在有用的工具。